2017 (3rd) International Symposium on Innovative Medicine Research & Development and Translational Strategy was successfully held by Sichuan Primed Bio-tech Group Co., Ltd., and Chengdu Primed HuaYing Bio-tech., Ltd. in Chengdu Medical Health Industry Promotion Office, The Management Committee of Chengdu Hi-tech Industrial Development Zone. It was sponsored by Merck Sharp & Dohme Corp, The Management Committee of Chengdu Tianfu International Bio-Industry Town, Sichuan Provincial People’s Hospital, West China hospital, and Hinova Pharmaceutical Inc. 

The launching ceremony of “Chronic Disease Database Consortium “was held at the start of the conference, there are 12 consortium members including hospitals, research centers and big pharma all over the world, such as Primed Bio-tech, West China hospital, Southern Medical University, Chinese Academy of Science, Tianjin TASLY Pharmaceutical Co., Ltd and so on. The purposes of the consortium is that the integration analysis of large database of Primed Chronic Disease can help us to analyze and explore the nature of life’s phenomena, and focuses on clinical transformation studies of cardiovascular disease, non-alcoholic fatty liver disease, liver fibrosis, eye diseases and neurological diseases could promote the original breakthrough in life sciences.
The symposium focuses on the latest development of disease models on non-alcoholic fatty liver diseases and liver fibroses, diabetic complications, heart failures, cognitive disorders and imaging technologies in the diagnosis of hepatic fibroses and other diseases.
21 experts and researchers from international institutes and labs including Merck Sharp & Dohme Corp, Brown University, Abbott, Chinese Academy of Sciences, West China Hospital at Sichuan University, and Fourth Military Medical University delivered keynote speeches concerning non-human primate models, new drug development and new diagnostic techiniques.

Dr. Jeffrey L. Evelhoch, who was the vice president of Merck Sharp & Dohme Corp, mentioned in the interview: “It is a combination of unique population of non-human primates and the group of people who are committed, highly-trained and skilled who are part of Primed. I think we are after a great start and the potential is huge. We are now at the point where the teams want actual studies here and start using what Primed has developed and keep building to move things further. I see the potential for a lot of the completed studies.”